- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01811121
MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS (RESECT)
Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional
Glioblastoma is the most frequent primary malignant brain tumor in adults (3,000 new cases per year) and is characterized by a poor prognosis (median survival 12 months). Treatment is based mainly on surgical excision as complete as possible followed by an additional radiochemotherapy. The prognosis depends mainly on the quality of resection when it is macroscopically complete. Different techniques to support the surgical resection have been developed over the past 20 years. The reference technique is currently the intraoperative neuronavigation for guiding excision by matching the intraoperative tumor boundaries with those of the preoperative MRI. Its main drawback is the loss of precision during the resection related to changes in anatomical limits of the tumor.
The per-operative fluorescence-guided surgery (FGS) is an innovative alternative technique to support the surgical resection. The 5-aminolevulinic acid (5-ALA), a molecule absorbed by the patient before surgery is captured specifically by the tumor cells and transformed into a fluorochrome revealed intraoperatively by a light source length adapted wave with a set of lenses included in the microscope. Resection is thus guided by this fluorescence whose disappearance translates complete tumor resection.
Its interest is twofold:
- Increase the percentage of complete tumor resection.
- Improve disease-free survival and overall survival. The objective of the study is to compare the FGS to the intraoperative neuronavigation for the resection of glioblastoma, on a medical and economical level through a randomized, prospective, multicenter trial.
The annual number of patients likely to benefit of this technique in France is estimated at 2200 new cases.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Lyon, France
- Guyotat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age greater than 18 years with no upper age limit
- Competent adult patient.
- Patient affiliated to the National Health Insurance.
- Patient with an intra-cerebral supra-tentorial hemispheric, newly diagnosed and previously untreated, which MRI characteristics are suggestive of a glioblastoma.
- Indication for surgical treatment by excision.
- Brain tumor location distant from critical functional areas allowing a wide resection of contrast enhancement on imaging, the a priori character completely resectable has been validated by an evaluation committee composed of three surgeons
- No-cons contain medical surgery, ASA score below 4.
- Patient eligible for further treatment by radiotherapy and concurrent chemotherapy followed by adjuvant chemotherapy according to the so called Stupp scheme (standard protocol of adjuvant chemoradiotherapy)
- Negative pregnancy test for women of childbearing age.
Exclusion Criteria:
Contraindications to performing an MRI (pacemaker).
- Glioblastoma known and previously treated with surgery, radiotherapy and / or chemotherapy.
- History of cancer.
- Anatomical Location of the tumor-cons indicating a wide excision, neurosurgeon at the discretion of medical officer participating center.
- Location tumor in the brain stem, the middle line, the basal ganglia and the posterior cranial fossa.
- Patient with cons-indication to the achievement of further treatment with radiotherapy and concurrent chemotherapy followed by adjuvant chemotherapy according to the scheme proposed by Stupp. (1)
- Patients with porphyria, renal insufficiency (creatinine> 177 μmolL), liver insufficency(gamma glutamyl transpeptidase> 100 U / L, prothrombin time <60%, bilirubin> 51μmol / L).
- Patient refused to sign an informed consent form.
- Ongoing participation of the patient to another clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 5-aminolévulinique acid (5-ALA)
5-aminolévulinique acid :microsurgical resection guided by fluorescence (CGF) in addition to the usual techniques of neuronavigation, after oral administration of 20mg/kg of 5-ALA 3-5 hours prior to surgical incision
|
oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
Other Names:
|
Placebo Comparator: Placebo
Laroscorbine :microsurgical excision guided solely by neuronavigation, after oral administration of a placebo 3 to 5 hours before the surgical incision
|
Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of complete tumor resection between the 2 arms
Time Frame: 48 hours
|
Evidenced of complete resection (absence of residual tumor on early postoperative MRI (within 48 hours)) will be assessed by a central independent committee with qualitative analysis of contrast enhancement replay on a console for diagnostic use.
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of complete tumor resection between the 2 arms
Time Frame: less than 48 hours after surgery
|
Evidenced of complete resection (absence of residual tumor on early postoperative MRI (within 48 hours)) will be assessed by the neurosurgeon who conducted the surgery and the neuro-radiologist who conducted the RMI with qualitative analysis of contrast enhancement replay during the initial clinical analysis
|
less than 48 hours after surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic value of the two intraoperative techniques
Time Frame: 60 months
|
Evaluate the sensitivity, specificity, positive predictive value and negative by correlating the results of pathological analysis of resection edge with intraoperative findings of the surgeon at the end of resection.
|
60 months
|
Quantification of residual tumor (contrast enhancement) on MRI post-opératre early (before 48 hours)
Time Frame: before 48 hours
|
It will be performed by three study investigators (Dr.
Pallud, Department of Neurosurgery, Centre Hospitalier Sainte-Anne, Paris; Dr. Guyotat, D department of Neurosurgery, Hospices Civils de Lyon, Lyon, Dr. Metellus, neurosurgery department, Assistance Publique - Hôpitaux de Marseille) and read separately.
The volume analysis will be done by segmentation using the OsiriX software on postoperative MRI and MRI pre-operative
|
before 48 hours
|
Progression Free survival rate at 6 months
Time Frame: 6 months
|
Progression is defined by the appearance of a new tumor lesion which minimum volume will be set to 0.175 cm3, by the increase of the residual tumor volume of 25% or more, or by the need to increase corticosteroid therapy.
The period of progression free survival is defined as the time from the date of tumor resection and date of diagnosis of tumor progression or the date last news or date of endpoint.
Progression Free survival rate at 6 months will be analyzed according to surgical approach used, according to the completeness or incompleteness of resection and by centers
|
6 months
|
Overall survival at 24 months
Time Frame: 24 months
|
It will be estimated from the number of patients who died of whatever cause.
The overall survival time is defined as the time between the date of tumor resection and date of death from any cause or date of last news or the date of endpoint.
The overall survival at 24 months will be analyzed according to surgical approach used, according to the completeness or incompleteness of resection and by centers.
|
24 months
|
Overall survival at 60 months
Time Frame: 60 months
|
It will be estimated from the number of patients who died of whatever cause.
The overall survival time is defined as the time between the date of tumor resection and date of death from any cause or date of last news or the date of endpoint.
The overall survival at 60 months will be analyzed according to surgical approach used, according to the completeness or incompleteness of resection and by centers.
|
60 months
|
Quality of life
Time Frame: every 3 months
|
Evaluation of quality of life every 3 months using the EORTC questionnaire QLQ-C30 with the specific brain tumors module BN20.
|
every 3 months
|
Evaluation of early and late morbidity
Time Frame: in 8 days and late morbidity at 3 months
|
Evaluation of early morbidity in 8 days and late morbidity at 3 months (neurological deficit, surgical site infection, secondary epilepsy, Karnofsky score, performance status WHO).
|
in 8 days and late morbidity at 3 months
|
Comparison of surgical procedure duration between the 2 arms
Time Frame: 60 months
|
60 months
|
|
Medico-economic evaluation of the 2 procedure
Time Frame: 60 months
|
Comparison of the differential cost effectiveness ratio between the 2 strategies
|
60 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jacques GUYOTAT, MD, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-697
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial ComponentUnited States, Canada, Australia, Israel, Taiwan, United Kingdom, Belgium, France, Spain, Germany, Austria, Brazil, Colombia, Czechia, Greece, Hungary, India, Italy, Mexico, Netherlands, New Zealand, Peru, Switzerland, Thailand
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
Clinical Trials on 5-aminolévulinique acid (5-ALA)
-
University of HawaiiSBI ALApromo Co., Ltd. - Strategic Business InnovatorCompletedStress | Insomnia | Irritability | Coping Behavior | Nocturnal AwakeningUnited States
-
Constantinos HadjipanayisNational Cancer Institute (NCI); NX PharmaGenWithdrawnGlioblastoma | Brain Cancer | Brain Tumors | Brain Tumor, Recurrent | Benign Neoplasms, Brain | Brain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Tumor, Primary | Intracranial Neoplasms | Neoplasms, Brain | Neoplasms, Intracranial | Primary Brain Neoplasms | Primary Malignant Brain Neoplasms | Primary Malignant... and other conditionsUnited States
-
Michael Vogelbaum, MD, PhDNational Cancer Institute (NCI)TerminatedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...Completed
-
University of WashingtonNational Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain TumorUnited States
-
medac GmbHCompletedBrain Cancer | Brain Tumors | Brain Tumor, Primary | Primary Brain Tumors | Cancer of Brain
-
David W. RobertsNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
NorthShore University HealthSystemWithdrawn
-
Sociedad de Lucha Contra el Cáncer del EcuadorNot yet recruitingGlioma | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Central Nervous System Neoplasms | Brain Tumor | High Grade Glioma | Glioma, Malignant | Neoplasm Malignant | Photosensitizing Agents | Tumour, Residual | Brain Neoplasms, Adult, MalignantEcuador
-
David W. RobertsNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting